gate-101
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Oct 26, 2020 (NCT04618263)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Metabotropic glutamate receptor 3ANTAGONIST
GRM3 antagonist
- Metabotropic glutamate receptor 2ANTAGONIST
GRM2 antagonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04618263 | Phase 1 | Oct 26, 2020 | Gate Neurosciences, Inc |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Gate Neurosciences, Inc | For profit | 1 | 1 | 1 | 2020 |
1 organizations
Page 1 / 1